Plasma cell myeloma
Not recruitingStudy Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
- Disease:Plasma cell myeloma
- Substances:DexamethasoneElotuzumab+3
Greece- Participants:18–64 years · 65+ years
- Substances:Dexamethasone
- Sponsor:European Myeloma Network B.V.















